Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

The meningococcal serogroup B (MenB) protein vaccine, 4CMenB, combined with MenA, MenC, MenW and MenY polysaccharide-protein conjugates for a pentavalent MenABCWY vaccine, can potentially protect against most causative agents of invasive meningococcal disease worldwide. Two phase 2b, randomized, mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesikari, Timo, Brzostek, Jerzy, Ahonen, Anitta, Paassilta, Marita, Majda-Stanislawska, Ewa, Szenborn, Leszek, Virta, Miia, Clifford, Robert, Jackowska, Teresa, Kimmel, Murray, Bindi, Ilaria, Keshavan, Pavitra, Pedotti, Paola, Toneatto, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828153/
https://www.ncbi.nlm.nih.gov/pubmed/34582323
http://dx.doi.org/10.1080/21645515.2021.1968214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828153/
https://www.ncbi.nlm.nih.gov/pubmed/34582323
http://dx.doi.org/10.1080/21645515.2021.1968214

Ejemplares similares